Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Citi
Accenture
Medtronic
Johnson and Johnson
US Army
Teva
US Department of Justice
Mallinckrodt

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020936

« Back to Dashboard

NDA 020936 describes PAXIL CR, which is a drug marketed by Apotex Technologies and is included in one NDA. It is available from four suppliers. Additional details are available on the PAXIL CR profile page.

The generic ingredient in PAXIL CR is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.
Summary for 020936
Tradename:PAXIL CR
Applicant:Apotex Technologies
Ingredient:paroxetine hydrochloride
Patents:0
Therapeutic Class:Antidepressants
Anxiolytics
Formulation / Manufacturing:see details
Pharmacology for NDA: 020936
Mechanism of ActionSerotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 020936
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936 NDA Rebel Distributors Corp 21695-159 E 21695-159-15
PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936 NDA Rebel Distributors Corp 21695-159 E 21695-159-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 12.5MG BASE
Approval Date:Feb 16, 1999TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 25MG BASE
Approval Date:Feb 16, 1999TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 37.5MG BASE
Approval Date:Dec 6, 2000TE:ABRLD:Yes

Expired US Patents for NDA 020936

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
UBS
Colorcon
Argus Health
Medtronic
Citi
Chinese Patent Office
Express Scripts
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.